Laekna, Inc.
2105.HK
Hong Kong Stock Exchange8.15
HKD
-0.09
- -
ISIN
KYG5340S1093
Return %
Stock
S&P500
1Y
-58.42
24.00
3Y
-45.67
69.49
5Y
-45.67
75.60
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Xiangyang Lu
- Full Time Employees
- 83
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3-2-467, 5 Xingbin Road Yuyao People's Republic of China
- IPO Date
- Jun 28, 2023
- Website
- laekna.com
- Similar Companies
- Business
- Laekna, Inc. engages in the discovery, development, and commercialization of cancer, metabolic disease, and liver fibrosis therapies, with a global focus on advancing novel oncology and related programs in China, the United States, and related markets; the company operates through integrated translational, clinical development, and BD functions to bring late-stage assets and pipeline candidates to regulatory approval and commercial valuation; headquarters are in China with operations extended to the U.S. and other regions, and it is listed on the Hong Kong Stock Exchange under ticker 2105.HK. Main products and services - Core therapeutic programs: LAE001 and LAE002, early to mid-stage drug candidates targeting cancer and SOC-resistant tumor indications; LAE102 and LAE105, discovery-to-clinical-stage inhibitors and agents for fibrosis and related hepatic conditions; multi-regional and single-region dossiers intended for registrational trials and potential commercialization; preclinical to Phase I/II transitions including IND filings and mechanistic studies to de-risk assets for later-stage development. - Clinical development services: design and execution of clinical trials (Phase I–III), pharmacology and translational studies, biomarker validation, patient stratification for MRCT programs, regulatory strategy and interactions, and global regulatory submissions for cancer and fibrosis therapies. - Research and discovery capabilities: target identification and validation for oncology and liver diseases; medicinal chemistry, lead optimization, pharmacokinetics/pharmacodynamics, and preclinical safety evaluation; in-house platforms for asset generation and evaluation. - Intellectual property and collaboration management: patent development and portfolio management, licensing negotiations, in-licensing and collaboration agreements with larger pharma groups and biotech partners; joint development and strategic alliance structures to accelerate reach of product candidates. Latest major company changes - Strategic partnerships and alliances: enters and expands research collaborations with multinational pharmaceutical developers to co-develop and co-commercialize select LAT and fibrosis programs, enhancing global reach and resource access. - Funding and capital movements: pursues multiple rounds of financing and strategic investments to support clinical trial execution and platform expansion; actively strengthens balance sheet through equity or debt instruments aligned with pipeline advancement. - Product and pipeline updates: advances LAE102 and LAE105 through IND/early clinical readouts; files INDs with major regulators (including FDA) for PI3Kα-selective inhibitors and other novel targets; expands MRCTs to address SOC-resistant cancer populations; progresses multiple registrational and pre-registrational studies across key programs. - Corporate and geographic expansion: strengthens integrated operations across China and the United States to streamline clinical development and regulatory pathways; increases in-house capabilities for rapid trial execution and global regulatory navigation; comprehensive ESG and governance practices updated to reflect growth and oversight standards. - Corporate actions: maintains listing on the main board of HKEX; governance refinements and corporate reorganizations aligned with expanded clinical operations and international partnerships. Industry context and context-specific notes - Industry focus: biotechnology with emphasis on oncology, metabolic diseases, and liver fibrosis; operates clinical development and early discovery for cancer therapies and fibrosis targets. - Target markets: China, United States, Europe, and other MRCT-centric regions; multi-regional clinical trials to support global approvals and potential commercialization. - Founding and structure: founded in 2016; headquarters historically associated with China-based operations and cross-border development teams in the U.S.; maintains subsidiaries and affiliate structures to manage regulatory, clinical, and BD activities.